NASDAQ:EARS

Auris Medical Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.15
+0.02 (+0.94 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.08
$2.19
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume87,333 shs
Average Volume3.10 million shs
Market Capitalization$24.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.


Auris Medical logo

About Auris Medical

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.91 out of 5 stars

Medical Sector

1247th out of 1,351 stocks

Pharmaceutical Preparations Industry

612th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What stocks does MarketBeat like better than Auris Medical?

Wall Street analysts have given Auris Medical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Auris Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd. (NASDAQ:EARS) released its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.80) by $1.60.
View Auris Medical's earnings history
.

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Shares of Auris Medical reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Who are Auris Medical's key executives?

Auris Medical's management team includes the following people:
  • Thomas Meyer, Chairman & Chief Executive Officer
  • Elmar Schärli, Chief Financial Officer
  • Samuel A. Wickline, Chief Scientific Officer
  • Andrea Vondraskova, Medical Director

What other stocks do shareholders of Auris Medical own?

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (3.54%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Squarepoint Ops LLC (0.09%).

Which institutional investors are selling Auris Medical stock?

EARS stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Citadel Advisors LLC.

Which institutional investors are buying Auris Medical stock?

EARS stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC, Group One Trading L.P., Squarepoint Ops LLC, Wells Fargo & Company MN, Cutler Group LP, and Susquehanna International Group LLP.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $2.15.

How much money does Auris Medical make?

Auris Medical has a market capitalization of $24.55 million.

How many employees does Auris Medical have?

Auris Medical employs 132,200 workers across the globe.

What is Auris Medical's official website?

The official website for Auris Medical is www.aurismedical.com.

Where are Auris Medical's headquarters?

Auris Medical is headquartered at Clarendon House 2 Church Street, Hamilton D0, HM 11.

How can I contact Auris Medical?

Auris Medical's mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology company can be reached via phone at (441) 295-5950 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.